CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Hold” by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned a consensus rating of “Hold” from the nineteen analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $71.50.

CRSP has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, July 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Saturday, September 27th. Chardan Capital reissued a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, September 23rd. Finally, Piper Sandler reissued an “overweight” rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, June 27th.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $67.74 on Monday. The business’s fifty day moving average price is $57.69 and its two-hundred day moving average price is $47.77. The stock has a market cap of $6.16 billion, a PE ratio of -12.48 and a beta of 1.84. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $73.95.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The business had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. During the same quarter last year, the firm earned ($1.49) earnings per share. The business’s revenue was up 72.5% on a year-over-year basis. As a group, equities research analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insider Activity

In other CRISPR Therapeutics news, Director Simeon George bought 989,812 shares of the company’s stock in a transaction dated Wednesday, July 16th. The shares were acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the transaction, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. The trade was a 133.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the company. Deutsche Bank AG boosted its position in shares of CRISPR Therapeutics by 65.0% during the fourth quarter. Deutsche Bank AG now owns 8,133 shares of the company’s stock worth $320,000 after buying an additional 3,205 shares during the period. AdvisorNet Financial Inc boosted its position in shares of CRISPR Therapeutics by 104.7% during the first quarter. AdvisorNet Financial Inc now owns 5,073 shares of the company’s stock worth $173,000 after buying an additional 2,595 shares during the period. GAMMA Investing LLC boosted its position in shares of CRISPR Therapeutics by 8,146.2% during the first quarter. GAMMA Investing LLC now owns 4,288 shares of the company’s stock worth $146,000 after buying an additional 4,236 shares during the period. 180 Wealth Advisors LLC boosted its position in shares of CRISPR Therapeutics by 22.9% during the first quarter. 180 Wealth Advisors LLC now owns 6,349 shares of the company’s stock worth $216,000 after buying an additional 1,182 shares during the period. Finally, Green Alpha Advisors LLC boosted its position in shares of CRISPR Therapeutics by 132.9% during the first quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company’s stock worth $1,952,000 after buying an additional 32,732 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.